AMLX

The past six months saw significant events for Amylyx Pharmaceuticals' stock, including positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) in August 2026, which met all endpoints and led to a substantial surge in AMLX shares. Following this, the company launched and upsized a public offering to fund pre-commercial activities for avexitide. Amylyx also participated in several investor conferences and held earnings calls, including the Stifel 2026 Virtual Cardiometabolic Forum, the 24th Annual Morgan Stanley Global Healthcare Conference, and its Second Quarter 2026 Earnings Conference Call. In the past three months, insiders sold over $2 million worth of company stock. A new U.S. ICD-10-CM code for post-bariatric hypoglycemia (E89.830) became effective on October 1, 2026, relevant to the avexitide program.